Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxandrolone in Multiligament Knee Reconstructions
NCT05893069Phase 4Suspended
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxandrolone in multi-ligament knee injury (MLKI) (2 arms). Primary endpoints: Lean Body Mass at 52 weeks and Body Fat Percentage at 52 weeks. Started Jul 2023; status: suspended.
02
Drugs
oxandrolone
03
Conditions
multi-ligament knee injury (MLKI)
Beyond the preview
Go deeper on NCT05893069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893069.